KalVista Pharmaceuticals (NASDAQ:KALV) Sets New 12-Month High Following Analyst Upgrade

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Friday after Stifel Nicolaus raised their price target on the stock from $39.00 to $42.00. Stifel Nicolaus currently has a buy rating on the stock. KalVista Pharmaceuticals traded as high as $19.27 and last traded at